# Cadent Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cadent-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.cadenttx.com
- Total disclosed funding: $53M
- Latest round: Series B (Apr 29, 2020)
- Investors on record: 8

## About

Cadent Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for neuropsychiatric disorders, utilizing novel mechanisms to address unmet medical needs in mental health care.Cadent Therapeutics, Inc. specializes in the development of therapies for neuropsychiatric disorders. The company was founded in 2010 and is headquartered in Cambridge, US. In December 2020, Novartis International AG agreed to acquire Cadent from various investors for an upfront payment of USD 210 mn, with additional milestone payments of up to USD 560 mn based on future achievements. The acquisition is anticipated to close in the first quarter of 2021. Cadent has successfully completed a total of 7 deals up to its most recent deal date.Cadent Therapeutics offers several innovative therapies targeting significant medical needs in neuropsychiatric disorders. These include MIJ821, a clinical-stage molecule designed for treatment-resistant depression, and CAD-9303, which addresses the negative and cognitive symptoms of schizophrenia. Additionally, CAD-1883 is in Phase II development for movement disorders. The company’s products are primarily marketed to healthcare professionals and patients across North America, Europe, and Asia-Pacific.Cadent Therapeutics generates revenue through product sales to healthcare providers and strategic partnerships with other pharmaceutical companies. Its revenue model includes direct sales of proprietary therapies, as well as collaboration agreements encompassing upfront payments, royalties, and further sales contingent on market success. Key products like MIJ821 are integral to the company's revenue strategy, supporting its commitment to developing transformative therapies.Cadent Therapeutics plans to leverage its recent acquisition by Novartis International AG to accelerate the development of its innovative therapies. The company aims to launch new products targeting various neuropsychiatric disorders in the coming years, with specific timelines dependent on ongoing clinical trials. Cadent is also looking to expand its market presence into new geographic regions, particularly within Europe and Asia by the end of 2021. The recent funding from the acquisition will be utilized to bolster research and development efforts, facilitating the advancement of its product pipeline.

## Funding rounds

- Series B, Apr 29, 2020, $15M — Atlas Venture, Healthcare Royalty Partners, Access Industries, Qiming Venture Partners, Clal Biotechnology, Novartis Institute for Biomedical Research
- Series B, Nov 15, 2018, $25M — Atlas Venture, Healthcare Royalty Partners, Access Industries, Qiming Venture Partners, Clal Biotechnology, Novartis Institute for Biomedical Research
- Series A, Jan 6, 2015, $3.9M — Atlas Venture, Clal Biotechnology
- Series A, Jun 20, 2013, $5.2M — Atlas Venture, Clal Biotechnology
- Series A, Feb 15, 2012, $3.2M — Slater Technology Fund, Access BridgeGap Ventures
- Seed, Jun 28, 2010, $0.3M — Slater Technology Fund

## Investors

- Slater Technology Fund (https://capitalatlas.ai/funds/slater-technology-fund) — Seed, Series A
- Access BridgeGap Ventures (https://capitalatlas.ai/funds/access-bridgegap-ventures) — Series A
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Clal Biotechnology (https://capitalatlas.ai/funds/clal-biotechnology) — Series A, Series B
- Healthcare Royalty Partners (https://capitalatlas.ai/funds/healthcare-royalty-partners) — Series B
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- Novartis Institute for Biomedical Research — Series B